Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1988 1
1995 2
1996 2
1997 2
1998 2
2000 1
2002 3
2003 3
2004 5
2005 4
2006 6
2007 9
2008 10
2009 9
2010 16
2011 10
2012 12
2013 12
2014 8
2015 4
2016 4
2017 4
2018 8
2019 6
2020 9
2021 11
2022 9
2023 12
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Results by year

Filters applied: . Clear all
Page 1
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. DiNardo CD, et al. Among authors: attar ec. N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2. N Engl J Med. 2018. PMID: 29860938 Free article. Clinical Trial.
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Sallman DA, et al. Among authors: attar ec. J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449813 Free PMC article. Clinical Trial.
Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, Deeg HJ, Sallman D, Gallacher P, Wennborg A, Hickman DK, Attar EC, Fernandez HF. Mishra A, et al. Among authors: attar ec. J Clin Oncol. 2022 Dec 1;40(34):3985-3993. doi: 10.1200/JCO.22.00181. Epub 2022 Jul 11. J Clin Oncol. 2022. PMID: 35816664
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM. Roboz GJ, et al. Among authors: attar ec. Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140. Blood. 2020. PMID: 31841594 Free PMC article. Clinical Trial.
Differentiating Polycystic Ovary Syndrome from Adrenal Disorders.
Yesiladali M, Yazici MGK, Attar E, Kelestimur F. Yesiladali M, et al. Among authors: attar e. Diagnostics (Basel). 2022 Aug 24;12(9):2045. doi: 10.3390/diagnostics12092045. Diagnostics (Basel). 2022. PMID: 36140452 Free PMC article. Review.
Experimental treatments of endometriosis.
Attar R, Attar E. Attar R, et al. Among authors: attar e. Womens Health (Lond). 2015 Aug;11(5):653-64. doi: 10.2217/whe.15.51. Epub 2015 Aug 28. Womens Health (Lond). 2015. PMID: 26314760 Free article. Review.
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Garcia-Manero G, Goldberg AD, Winer ES, Altman JK, Fathi AT, Odenike O, Roboz GJ, Sweet K, Miller C, Wennborg A, Hickman DK, Kanagal-Shamanna R, Kantarjian H, Lancet J, Komrokji R, Attar EC, Sallman DA. Garcia-Manero G, et al. Among authors: attar ec. Lancet Haematol. 2023 Apr;10(4):e272-e283. doi: 10.1016/S2352-3026(22)00403-3. Lancet Haematol. 2023. PMID: 36990622 Clinical Trial.
Genomics in Egypt: Current Status and Future Aspects.
El-Attar EA, Helmy Elkaffas RM, Aglan SA, Naga IS, Nabil A, Abdallah HY. El-Attar EA, et al. Front Genet. 2022 May 13;13:797465. doi: 10.3389/fgene.2022.797465. eCollection 2022. Front Genet. 2022. PMID: 35664315 Free PMC article. Review.
Steroidogenic factor-1 and endometriosis.
Bulun SE, Utsunomiya H, Lin Z, Yin P, Cheng YH, Pavone ME, Tokunaga H, Trukhacheva E, Attar E, Gurates B, Milad MP, Confino E, Su E, Reierstad S, Xue Q. Bulun SE, et al. Among authors: attar e. Mol Cell Endocrinol. 2009 Mar 5;300(1-2):104-8. doi: 10.1016/j.mce.2008.12.012. Epub 2008 Dec 25. Mol Cell Endocrinol. 2009. PMID: 19150483 Review.
161 results